Drug
Fimepinostat clinical trials
Also written CUDC-907.
Keep track of what changes. Save the fimepinostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 3 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 4
Curis, Inc. (2) · Sabine Mueller, MD, PhD (1) · Dana-Farber Cancer Institute (1) · University of California, Los Angeles (1) · National Cancer Institute (NCI) (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses fimepinostat is read from its arms, and is right about nine times in ten.
Testing it · 6
- Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseRecruitingPhase 2University of California, Los AngelesNCT05971758Written as Fimepinostat
- Fimepinostat in Treating Brain Tumors in Children and Young AdultsActive, not recruitingEarly Phase 1Sabine Mueller, MD, PhDNCT03893487Written as Fimepinostat
- Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaCompletedPhase 1Dana-Farber Cancer InstituteNCT02909777Written as CUDC-907
- Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsCompletedPhase 2Curis, Inc.NCT02674750Written as CUDC-907
- Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsCompletedPhase 1Curis, Inc.NCT02307240Written as CUDC-907
- CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03002623Written as CUDC-907
Given in every arm · 1 — fimepinostat is usual care beside what is tested
Codes
What other systems call fimepinostat · ClinicalTrials.gg INT006195
- MeSH (NLM) C000723994fimepinostatOne source ClinicalTrials.gov
- UNII (FDA) 3S9RX35S5XFIMEPINOSTATOne source FDA
- NCI Thesaurus C104008FimepinostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723994 | fimepinostat | One source ClinicalTrials.gov |
| UNII (FDA) | 3S9RX35S5X | FIMEPINOSTAT | One source FDA |
| NCI Thesaurus | C104008 | Fimepinostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.